XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.2

REVENUES (Tables)

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

The following table summarizes our Total revenues:

						Three Months Ended June 30, 2022																								Three Months Ended June 30, 2021
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product sales:
HIV
Biktarvy						$	2,095					$	268					$	193					$	2,556					$	1,586					$	237					$	171					$	1,994
Complera/Eviplera						20						31						3						54						20						39						3						62
Descovy						397						32						32						460						357						44						34						435
Genvoya						482						72						29						582						551						100						55						706
Odefsey						255						97						12						364						258						111						13						382
Stribild						24						8						2						33						35						11						5						51
Truvada						24						5						5						34						94						6						8						108
Revenue share - Symtuza(1)						80						42						4						126						86						40						3						129
Other HIV(2)						5						9						4						18						57						8						6						71
Total HIV						3,383						562						282						4,228						3,044						596						298						3,938
Veklury						41						126						278						445						416						264						149						829
Hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)						6						4						13						23						30						3						29						62
Sofosbuvir/Velpatasvir(4)						227						75						74						376						262						82						98						442
Other HCV(5)						30						16						3						49						35						8						2						45
Total HCV						263						94						91						448						327						93						129						549
Hepatitis B virus (“HBV”) / Hepatitis delta virus (“HDV”)
Vemlidy						97						9						89						195						86						8						106						200
Viread						3						6						15						24						3						8						17						28
Other HBV/HDV(6)						—						15						—						16						1						8						—						9
Total HBV/HDV						100						30						104						234						90						24						123						237
Cell therapy
Tecartus						53						20						—						73						32						9						—						41
Yescarta						193						85						17						295						108						61						9						178
Total cell therapy						246						105						17						368						140						70						9						219
Trodelvy						120						35						3						159						89						—						—						89
Other
AmBisome						15						63						54						132						13						69						74						156
Letairis						49						—						—						49						57						—						—						57
Other(7)						37						26						13						76						37						31						10						78
Total other						101						88						67						256						107						100						84						291
Total product sales						4,254						1,042						842						6,138						4,213						1,147						792						6,152
Royalty, contract and other revenues						85						34						2						122						20						45						—						65
Total revenues						$	4,339					$	1,076					$	844					$	6,260					$	4,233					$	1,192					$	792					$	6,217

						Six Months Ended June 30, 2022																								Six Months Ended June 30, 2021
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product sales:
HIV
Biktarvy						$	3,801					$	529					$	376					$	4,707					$	3,051					$	453					$	314					$	3,818
Complera/Eviplera						37						55						7						99						45						73						7						125
Descovy						708						64						63						834						639						86						69						794
Genvoya						939						149						76						1,164						1,057						206						116						1,379
Odefsey						487						193						23						703						498						224						27						749
Stribild						46						16						5						66						66						22						9						97
Truvada						52						9						11						72						213						13						17						243
Revenue share - Symtuza(1)						166						86						6						258						175						84						5						264
Other HIV(2)						10						13						9						33						86						13						20						119
Total HIV						6,245						1,112						577						7,935						5,830						1,174						584						7,588
Veklury						843						430						708						1,980						1,236						652						397						2,285
HCV
Ledipasvir/Sofosbuvir(3)						19						8						31						58						49						19						50						118
Sofosbuvir/Velpatasvir(4)						389						157						159						706						476						157						190						823
Other HCV(5)						54						24						5						83						60						52						6						118
Total HCV						462						189						196						847						585						228						246						1,059
HBV/HDV
Vemlidy						177						18						199						394						163						16						202						381
Viread						3						12						32						47						7						15						37						59
Other HBV/HDV(6)						—						28						—						28						1						16						—						17
Total HBV/HDV						180						57						232						470						171						47						239						457
Cell therapy
Tecartus						100						35						1						136						59						13						—						72
Yescarta						318						162						26						506						200						122						16						338
Total cell therapy						418						197						27						642						259						135						16						410
Trodelvy						240						61						5						305						161						—						—						161
Other
AmBisome						40						129						107						275						25						135						117						277
Letairis						92						—						—						92						111						—						—						111
Other(7)						63						41						22						125						75						51						18						144
Total other						195						169						129						493						211						186						135						532
Total product sales						8,582						2,216						1,873						12,672						8,453						2,422						1,617						12,492
Royalty, contract and other revenues						112						61						5						178						40						106						2						148
Total revenues						$	8,694					$	2,277					$	1,878					$	12,850					$	8,493					$	2,528					$	1,619					$	12,640

_______________________________

(1)     Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

(2)     Includes Atripla, Emtriva and Tybost.

(3)     Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)     Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)     Includes Vosevi and Sovaldi.

(6)     Includes Hepcludex and Hepsera.

(7)     Includes Cayston, Jyseleca, Ranexa and Zydelig.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:

						Three Months Ended												Six Months Ended
						June 30,												June 30,
(as a percentage of total revenues)						2022						2021						2022						2021
AmerisourceBergen Corporation						17		%				21		%				18		%				24		%
Cardinal Health, Inc.						26		%				23		%				24		%				21		%
McKesson Corporation						20		%				17		%				20		%				17		%

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior periods:

						Three Months Ended												Six Months Ended
						June 30,												June 30,
(in millions)						2022						2021						2022						2021
Revenue share with Janssen and royalties for licenses of intellectual property						$	197					$	209					$	381					$	435
Changes in estimates						$	16					$	141					$	246					$	473

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of expected timing for satisfying remaining performance obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration